Multicomponent Injectable Hydrogels for Antigen‐Specific Tolerogenic Immune Modulation
- 24 January 2017
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 6 (6)
Abstract
Biomaterial scaffolds that enrich and modulate immune cells in situ can form the basis for potent immunotherapies to elicit immunity or reëstablish tolerance. Here, the authors explore the potential of an injectable, porous hydrogel to induce a regulatory T cell (Treg) response by delivering a peptide antigen to dendritic cells in a noninflammatory context. Two methods are described for delivering the BDC peptide from pore‐forming alginate gels in the nonobese diabetic mouse model of type 1 diabetes: encapsulation in poly(lactide‐co‐glycolide) (PLG) microparticles, or direct conjugation to the alginate polymer. While particle‐based delivery leads to antigen‐specific T cells responses in vivo, PLG particles alter the phenotype of the cells infiltrating the gels. Following gel‐based peptide delivery, transient expansion of endogenous antigen‐specific T cells is observed in the draining lymph nodes. Antigen‐specific T cells accumulate in the gels, and, strikingly, ≈60% of the antigen‐specific CD4+ T cells in the gels are Tregs. Antigen‐specific T cells are also enriched in the pancreatic islets, and administration of peptide‐loaded gels does not accelerate diabetes. This work demonstrates that a noninflammatory biomaterial system can generate antigen‐specific Tregs in vivo, which may enable the development of new therapies for the treatment of transplant rejection or autoimmune diseases.Keywords
Funding Information
- Juvenile Diabetes Research Foundation (5-2011-434)
- National Institutes of Health (1R01DE019917)
This publication has 50 references indexed in Scilit:
- De Novo Malignancies After TransplantationMedical Clinics of North America, 2016
- T cell receptor signalling in the control of regulatory T cell differentiation and functionNature Reviews Immunology, 2016
- Melanoma Risk and Survival among Organ Transplant RecipientsJournal of Investigative Dermatology, 2015
- Control of Regulatory T Cell Migration, Function, and HomeostasisThe Journal of Immunology, 2015
- Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8+ T LymphocytesImmunity, 2015
- Trials in type 1 diabetes: Antigen-specific therapiesClinical Immunology, 2013
- Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD miceJournal of Experimental Medicine, 2007
- Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune diseaseImmunological Reviews, 2006
- Antigen-Specific FoxP3-Transduced T-Cells Can Control Established Type 1 DiabetesDiabetes, 2005
- CD25+ CD4+ T Cells, Expanded with Dendritic Cells Presenting a Single Autoantigenic Peptide, Suppress Autoimmune DiabetesJournal of Experimental Medicine, 2004